SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal - Quaterly Results

08 Feb 2024 Evaluate
A decrease in the sales to Rs. 4475.70 millions was observed for the quarter ended December 2023. The sales stood at Rs. 5402.00 millions during the similar quarter previous year.Net Profit of the company move down -38.39% to Rs. 162.70  millions from Rs. 264.10 millions  in the same quarter last year.Operating profit for the quarter ended December 2023 decreased to 649.50 millions as compared to 770.90 millions of corresponding quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 4475.70 5402.00 -17.15 12705.00 14777.40 -14.02 20230.30 19427.20 4.13
Other Income 0.60 25.10 -97.61 19.90 70.30 -71.69 54.10 48.90 10.63
PBIDT 649.50 770.90 -15.75 1745.80 1740.10 0.33 2624.70 3454.50 -24.02
Interest 142.40 130.30 9.29 411.10 351.20 17.06 481.00 312.10 54.12
PBDT 507.10 640.60 -20.84 1334.70 1388.90 -3.90 2143.70 3142.40 -31.78
Depreciation 289.70 282.70 2.48 852.70 821.80 3.76 1090.10 956.70 13.94
PBT 217.40 357.90 -39.26 482.00 567.10 -15.01 1053.60 2185.70 -51.80
TAX 54.70 93.80 -41.68 125.50 144.00 -12.85 269.80 580.60 -53.53
Deferred Tax 3.10 -10.50 -129.52 1.70 -13.80 -112.32 -35.00 -15.90 120.13
PAT 162.70 264.10 -38.39 356.50 423.10 -15.74 783.80 1605.10 -51.17
Equity 246.60 246.60 0.00 246.60 246.60 0.00 246.60 246.60 0.00
PBIDTM(%) 14.51 14.27 1.69 13.74 11.78 16.69 12.97 17.78 -27.04

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×